drugset
drugset / Trial / NCT02393599

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599 ↗

Phase 1 Completed 20 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupTriple-blindDiagnostic

Summary

The primary objective of this study is to determine if there are significant interactions between oral lorcaserin treatment concurrent with 20 and 40 mg intravenous (i.v.) cocaine infusions by measuring adverse events (AEs) and cardiovascular responses including heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) (including QTc).

Timeline

Start
2015-05
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cocaine Small molecule 20 mg Intravenous
Subject Cocaine Small molecule 40 mg Intravenous
Subject Lorcaserin Small molecule 10 mg Oral

Indications

cocaine abuse